AbCellera and Jazz Pharmaceuticals strike a preclinical T cell engager deal worth up to $4.1B targeting gastrointestinal and other solid tumor cancers across up to five programs.
For much of its first decade, Canadian antibody developer AbCellera signed partnership after partnership, securing 40 biopharma alliances that led to more than a dozen …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Jazz zeroes in on next-gen T cell engagers with AbCellera deal
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration - AbCellera Biologics (NASD
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
Lilly oncology chief went from ‘extremely nervous’ to ‘blown away’ by new Jaypirca CLL data
EHA: J&J sharpens myeloma edge as Talvey, Darzalex Faspro combo proves its worth in earlier disease stage
Lonza Issues Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation Dual Payload ADCs for Gastrointestinal Cancers
